Notice: This company has been marked as potentially delisted and may not be actively trading. Bioanalytical Systems (BASI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends BASI vs. PIRS, LUNA, ISPC, NOTV, ONMD, BIAF, AIKI, DKDCA, FOXO, and PGENShould you be buying Bioanalytical Systems stock or one of its competitors? The main competitors of Bioanalytical Systems include Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), iSpecimen (ISPC), Inotiv (NOTV), OneMedNet (ONMD), bioAffinity Technologies (BIAF), AIkido Pharma (AIKI), Data Knights Acquisition (DKDCA), FOXO Technologies (FOXO), and Precigen (PGEN). Bioanalytical Systems vs. Pieris Pharmaceuticals Luna Innovations iSpecimen Inotiv OneMedNet bioAffinity Technologies AIkido Pharma Data Knights Acquisition FOXO Technologies Precigen Pieris Pharmaceuticals (NASDAQ:PIRS) and Bioanalytical Systems (NASDAQ:BASI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends. Which has more risk and volatility, PIRS or BASI? Pieris Pharmaceuticals has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Bioanalytical Systems has a beta of 1.92, indicating that its share price is 92% more volatile than the S&P 500. Is PIRS or BASI more profitable? Bioanalytical Systems has a net margin of -7.75% compared to Pieris Pharmaceuticals' net margin of -39.71%. Bioanalytical Systems' return on equity of -42.74% beat Pieris Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Pieris Pharmaceuticals-39.71% -101.29% -65.00% Bioanalytical Systems -7.75%-42.74%-6.38% Do institutionals and insiders hold more shares of PIRS or BASI? 40.1% of Pieris Pharmaceuticals shares are held by institutional investors. Comparatively, 10.6% of Bioanalytical Systems shares are held by institutional investors. 8.9% of Pieris Pharmaceuticals shares are held by company insiders. Comparatively, 11.5% of Bioanalytical Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community prefer PIRS or BASI? Pieris Pharmaceuticals received 150 more outperform votes than Bioanalytical Systems when rated by MarketBeat users. Likewise, 60.70% of users gave Pieris Pharmaceuticals an outperform vote while only 38.79% of users gave Bioanalytical Systems an outperform vote. CompanyUnderperformOutperformPieris PharmaceuticalsOutperform Votes27860.70% Underperform Votes18039.30% Bioanalytical SystemsOutperform Votes12838.79% Underperform Votes20261.21% Which has stronger earnings & valuation, PIRS or BASI? Bioanalytical Systems has higher revenue and earnings than Pieris Pharmaceuticals. Bioanalytical Systems is trading at a lower price-to-earnings ratio than Pieris Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPieris Pharmaceuticals$42.81M0.53-$24.54M-$18.71-0.92Bioanalytical Systems$60.47M0.33-$4.68M-$0.35-5.09 Does the media refer more to PIRS or BASI? In the previous week, Pieris Pharmaceuticals had 1 more articles in the media than Bioanalytical Systems. MarketBeat recorded 1 mentions for Pieris Pharmaceuticals and 0 mentions for Bioanalytical Systems. Bioanalytical Systems' average media sentiment score of 0.00 beat Pieris Pharmaceuticals' score of -0.18 indicating that Bioanalytical Systems is being referred to more favorably in the news media. Company Overall Sentiment Pieris Pharmaceuticals Neutral Bioanalytical Systems Neutral Do analysts rate PIRS or BASI? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pieris Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ABioanalytical Systems 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A SummaryBioanalytical Systems beats Pieris Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get Bioanalytical Systems News Delivered to You Automatically Sign up to receive the latest news and ratings for BASI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BASI vs. The Competition Export to ExcelMetricBioanalytical SystemsCommercial Physical Research IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.81M$4.58B$5.39B$8.53BDividend YieldN/A1.71%5.13%4.14%P/E Ratio-4.2460.14113.8115.12Price / Sales0.3360.861,483.2593.03Price / Cash558.4023.5039.6434.05Price / Book2.582.884.665.02Net Income-$4.68M$140.16M$119.06M$225.46M Bioanalytical Systems Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BASIBioanalytical SystemsN/A$1.78+0.6%N/A-4.8%$19.81M$60.47M-4.24397Analyst ForecastPIRSPieris Pharmaceuticals2.3762 of 5 stars$17.00+0.4%N/A-14.4%$22.44M$20.87M-0.91140LUNALuna Innovations2.0298 of 5 stars$1.81flat$8.00+342.0%-70.9%$61.47M$116.61M-22.63337Analyst ForecastISPCiSpecimen1.3738 of 5 stars$4.32-8.7%N/A+561.0%$56.48M$10.51M-0.2060Upcoming EarningsNews CoverageNOTVInotiv1.6894 of 5 stars$1.82+6.4%$5.92+225.1%-4.3%$47.27M$501.06M-0.472,055Positive NewsONMDOneMedNetN/A$0.86-5.5%N/AN/A$20.51M$1.02M-4.532Gap DownBIAFbioAffinity Technologies1.9216 of 5 stars$1.35-3.6%$6.00+344.4%+7.0%$15.74M$7.32M-1.4710Short Interest ↑AIKIAIkido PharmaN/A$1.75-1.7%N/A-15.0%$9.60M$10,000.00-0.454Gap DownDKDCAData Knights AcquisitionN/A$0.86-5.5%N/A-86.9%$4.45MN/A-4.532High Trading VolumeFOXOFOXO TechnologiesN/A$0.14-6.5%N/AN/A$1.95M$140,000.000.003PGENPrecigen4.3109 of 5 stars$0.84-1.2%$7.00+728.6%-23.7%$213.53M$6.22M-1.56202Positive News Related Companies and Tools Related Companies Pieris Pharmaceuticals Competitors Luna Innovations Competitors iSpecimen Competitors Inotiv Competitors OneMedNet Competitors bioAffinity Technologies Competitors AIkido Pharma Competitors Data Knights Acquisition Competitors FOXO Technologies Competitors Precigen Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BASI) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioanalytical Systems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioanalytical Systems With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
